Recommendations for the critical reading of clinical trials on disease-modifying drugs for multiple sclerosis
Introduction In recent years there has been an increase in the number of disease-modifying drugs (DMDs) approved for multiple sclerosis (MS). The evidence of their safety and efficacy has been obtained through several phase III […]
